L26/O-272 Targeting insulin resistance prior to in vitro fertilisation cycle in women with polycystic ovary syndrome and metabolic syndrome: a prospective cohort study
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.270 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von M. Khmil und 10 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Does 8–12-week metabolic optimization before in vitro fertilization cycles improve outcomes in women with PCOS and metabolic syndrome, and can a prognostic model predict effectiveness? Summary answer Metabolic optimization substantially improves insulin resistance and the androgen profile, reduces ovarian stimulation burden, increases the number of mature oocytes, and improves fertilization and implantation. What is known already PCOS is a leading cause of anovulatory infertility. Concomitant metabolic syndrome is associated with a more severe clinicsl features (insulin resistance, dyslipidaemia, hyperandrogenism, central obesity), potentially impairing ovarian responsiveness, oocyte/embryo quality and endometrial receptivity, thereby reducing ART success. However, routine practice lacks quantitative tools to assess the degree of metabolic compensation before IVF and to forecast treatment effectiveness, limiting the ability to personalize preconception preparation in PCOS with metabolic syndrome. Study design, size, duration Prospective cohort study over a 3-year period including 128 infertile reproductive-aged women with PCOS undergoing IVF. Participants were allocated to three groups: PCOS and MetS group with routine preparation (folic acid 400 μg/day; n = 43); PCOS and MetS group receiving 8–12 weeks of metabolic optimisation (myo-inositol 2000 mg/day, metformin 1000 mg/day, alpha-lipoic acid 600 mg/day, alongside a hypocaloric diet and daily physical activity; n = 44); and only PCOS group receiving standard preparation (n = 41). Participants/materials, setting, methods Before IVF, we measured HOMA-IR, lipid profile, LH/FSH ratio, total/free testosterone, FAI, SHBG, BMI. ART outcomes were stimulation length, gonadotropin dose, OSI, MII oocyte yield, 2PN fertilisation, and blastulation. Ovarian stimulation monitoring was standardized using AI-based automated folliculometry. Frozen-thawed transfer outcomes were implantation, clinical pregnancy, live birth per transfer, and early loss. METRO-PCOS was developed via logistic regression and a 0–2 point score per predictor (total 0–14) to stratify metabolic compensation and guide pre-treatment. Main results and the role of chance Compared with standard preparation in PCOS+MetS, metabolic optimization significantly improved metabolic markers (HOMA-IR −37.7%; total cholesterol −17.2%, triglycerides −29.2%, LDL −22.5%, HDL +33.3%; all p < 0.05) and androgen/gonadotropin profile (LH/FSH −39.6%, total testosterone −61.3%, free testosterone −52.3%, SHBG +48.6%). Stimulation outcomes improved (shorter stimulation, lower gonadotropin requirement, higher MII yield and proportion), with higher 2PN fertilization (85.2% vs 76.1%) and blastulation (63.57% vs 55.62%) due to routine treatment group (p < 0.05). Implantation, clinical pregnancy and live birth per embryo transfer were higher but did not reach statistical significance (p > 0.05), while early pregnancy loss decreased. Correlation and regression analyses supported the prognostic framework: BMI, waist circumference, HOMA-IR, total testosterone and SHBG were independently associated with embryological and clinical endpoints (p < 0.05), with the strongest negative associations observed for HOMA-IR (up to r = −0.51). The final METRO-PCOS score included six variables (BMI, waist circumference, HOMA-IR, total testosterone, SHBG and 25(OH)D) and demonstrated good discrimination (ROC AUC 0.82; sensitivity 78%; specificity 81%). Lower scores indicated compensated status suitable for proceeding to stimulation, whereas higher scores suggested the need for extended/intensified metabolic optimization before IVF.The novelty of our study lies in demonstrating that even a short course of metabolic optimization can significantly improve embryo developmental quality. Limitations, reasons for caution Non-randomised allocation and single-centre design may introduce selection bias. Several clinical endpoints were underpowered and did not reach statistical significance; external validation and adequately powered randomised studies are required, particularly for live birth. Wider implications of the findings In PCOS+MetS, structured preconception metabolic optimization is associated with better stimulation efficiency and embryo developmental competence. METRO-PCOS provides a simple, scalable tool to quantify metabolic compensation, personalise the duration of pre-IVF preparation and stratify prognosis, while AI-based folliculometry supports standardized, reproducible stimulation monitoring in routine practice. Trial registration number No
Zitieren
APA
Khmil, M., Khmil, S., Doswald, A. K., Pravak, Y., Tsependa, O., Makohonenko, I., Kushnir, A., Stanchak, K., Khasyshyn, N., Venher, H., & Koltun-Ponomarenko, Y. (2026). L26/O-272 Targeting insulin resistance prior to in vitro fertilisation cycle in women with polycystic ovary syndrome and metabolic syndrome: a prospective cohort study. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.270
Vancouver
Khmil M, Khmil S, Doswald AK, Pravak Y, Tsependa O, Makohonenko I, et al. L26/O-272 Targeting insulin resistance prior to in vitro fertilisation cycle in women with polycystic ovary syndrome and metabolic syndrome: a prospective cohort study. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.270
BibTeX
@article{Khmil2026,
author = {Khmil, M. and Khmil, S. and Doswald, A. Khmil and Pravak, Y. and Tsependa, O. and Makohonenko, I. and Kushnir, A. and Stanchak, K. and Khasyshyn, N. and Venher, H. and Koltun-Ponomarenko, Y.},
title = {L26/O-272 Targeting insulin resistance prior to in vitro fertilisation cycle in women with polycystic ovary syndrome and metabolic syndrome: a prospective cohort study},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.270}
}
EUVIMED